Table 4. Prevalence of medically diagnosed symptoms, and unadjusted and adjusted odds ratios (OR) derived from logistic regression models, in human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3a.
| Symptoms | HTLV seronegative (N = 799) | HTLV-I (N = 152) | HTLV-II (N = 387) | ||||
|---|---|---|---|---|---|---|---|
| Cases (%)b | Cases (%)b | ORc | Adj. OR (95% CI)d | Cases (%)b | ORc | Adj. OR (95% CI)d | |
| Trouble walking, climbing or rising from chair | 147 (21) | 52 (42) | 2.71 | 2.67 (1.74 to 4.09) | 133 (42) | 2.78 | 3.44 (2.52 to 4.71) |
| Incontinence, pre- or post-void urgency | 175 (25) | 50 (40) | 2.03 | 2.02 (1.33 to 33.07) | 134 (43) | 2.25 | 2.59 (1.92 to 3.49) |
| Lymphadenopathy | 29 (4) | 11 (9) | 2.26 | 2.39 (1.14 to 5.03) | 40 (13) | 3.40 | 3.08 (1.85 to 5.13) |
| Night sweats | 20 (3) | 15 (12) | 4.68 | 4.73 (2.31 to 9.69) | 47 (15) | 6.02 | 4.97 (2.77 to 8.94 |
| Weight loss | 40 (6) | 9 (7) | 1.29 | 1.10 (0.51 to 2.37) | 40 (13) | 2.43 | 2.10 (1.22 to 3.60) |
| Foot paresthesias | 57 (8) | 22 (18) | 2.44 | 2.46 (1.41 to 4.28 | 66 (21) | 3.02 | 3.27 (2.19 to 4.88) |
| Impotence (males only) | 33 (5) | 10 (8) | 2.24 | 2.05 (0.77 to 5.49) | 13 (4) | 1.10 | 1.27 (0.56 to 2.91) |
aOnly the first diagnosis of each symptom is considered for each participant. bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis. cUnadjusted. dAdjusted. Models were adjusted for age, race and ethnicity, and duration of follow-up (all symptoms), and gender (all except impotence). In addition, specific models included community versus autologous donation (for trouble walking and incontinence, weight loss and impotence.) and injection drug use [night sweats and weight loss]).